Anti-Human HLA-DR (MHC Class II) [Clone L243] — Purified in vivo GOLD™ Functional Grade
Anti-Human HLA-DR (MHC Class II) [Clone L243] — Purified in vivo GOLD™ Functional Grade
Product No.: H261
Clone L243 Target HLA-DR Formats AvailableView All Product Type Monoclonal Antibody Alternate Names Major Histocompatibility Class II, MHC class II, HLA-DR Monomorphic Isotype Mouse IgG2a Applications B , CyTOF® , Depletion , FC , IHC FF , in vivo , IP , PhenoCycler® , WB |
Antibody DetailsProduct DetailsReactive Species Baboon ⋅ Chimpanzee ⋅ Cynomolgus Monkey ⋅ Marmoset ⋅ Rhesus Monkey ⋅ Squirrel Monkey ⋅ Canine ⋅ Human Host Species Mouse Recommended Isotype Controls Recommended Dilution Buffer Immunogen Unknown Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2737519 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for this HLA-DR (Clone L243) antibody for staining cells in flow cytometry is ≤ 0.5 μg per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
WB The suggested concentration for this HLA-DR (Clone L243) antibody for use in western blotting is 1-10 μg/ml. Additional Applications Reported In Literature ? IHC FF CyTOF® B Depletion IP Additional Reported Applications For Relevant Conjugates ? CODEX® Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone L243 recognizes a conformational epitope on the human MHC class II molecule HLA-DRα, which depends on the correct folding of the αβ heterodimer1. It does not cross-react with HLA-DP or HLA-DQ. Background HLA-DR antibody, clone L243, recognizes the major histocompatibility complex (MHC) class II molecule Human Leukocyte Antigen - DR isotype (HLA-DR). MHC class II is constitutively expressed on human professional antigen-presenting cells (APCs), including macrophages/monocytes, dendritic cells (DCs), and B cells, and is induced on T cells upon activation2. HLA-DR consists of two transmembrane proteins, a 35 kDa α (heavy) chain and 29 kDa β (light) chain3 encoded by the HLA-DRA and HLA-DRB1, HLA-DRB3, HLA-DRB4, and HLA-DRB5 genes, respectively, located in the HLA complex of chromosome 6. The N-terminal α1 and β1 domains form the antigen-binding groove, which binds 13-25 aa peptides derived from exogenous antigens4. On APCs, MHC class II plays a critical role in the adaptive immune response by presenting phagocytosed antigens to helper CD4 T cells. The T cell receptor (TCR)/CD3 complex of CD4 T cells interacts with peptide-MHC class II, which induces CD4 T cell activation leading to the coordination and regulation of other effector cells. CD4 molecules also bind to MHC class II, which helps augment TCR signaling5. It has also been demonstrated that MHC class II express on activated T cells are capable of antigen presentation6 and can transduce signals into T cells, enhancing T cell proliferation and activity7. HLA-DR expression is a marker of T cell activation and correlates with disease activity in patients with autoimmune disease8 and rapid progression in HIV infection9. Specific alleles of HLA-DR are associated with autoimmune diseases, including rheumatoid arthritis10.
Antigen Distribution HLA-DR is expressed on antigen-presenting cells, including macrophages, monocytes, DCs, and B cells, and activated T cells. Ligand/Receptor CD3/TCR, CD4 Function Peptide presentation PubMed NCBI Gene Bank ID Research Area Immunology . Innate Immunity Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. In Vivo Applications of Clone L243 in MiceClone L243 is a mouse monoclonal antibody (IgG2a) that specifically binds to the human HLA-DR (MHC class II) antigen. While it is primarily designed for human studies, its use extends to certain mouse applications, especially in xenograft or humanized mouse models. Direct In Vivo UseGiven that L243 is specific to human HLA-DR, its direct in vivo applications in wild-type mice are limited. Mice express their own MHC class II molecules (I-A, I-E), not human HLA-DR, so L243 does not recognize murine MHC class II and cannot be used for immunoprecipitation, cell depletion, or functional blockade in regular mice. However, L243 can be used in vivo in humanized mouse models—mice engrafted with human cells or tissues expressing HLA-DR, such as human tumor xenografts or immune system humanized models. In these contexts, L243 can be used for:
Indirect Applications
Typical Applications (Primarily In Vitro or Ex Vivo)
Summary Table
Key Points
In conclusion, clone L243’s main in vivo applications in mice are limited to models where human HLA-DR is present, such as in humanized or HLA-DR-transgenic mice. Here, it is used for targeted depletion, functional blockade, and immunological studies of human cells in a murine host. The most commonly used antibodies and proteins with L243 (anti-HLA-DR) in the literature are other antibodies targeting cell lineage or differentiation markers and functional probes in multi-antibody panels, as well as those used in combination therapy research. Most notably:
Key applications of these combinations include:
Other less commonly cited antibodies or proteins:
In summary, frequently used antibodies/proteins with L243 include anti-CD20 (rituximab), other anti-HLA-DR clones, lineage markers (CD3, CD4, CD19), IFNα, and isotype/secondary controls. Key findings from scientific literature citing clone L243 focus on its specificity, epitope recognition, non-cross-reactivity, and broad use in immune profiling of human and non-human primate cells:
In summary, clone L243 is a gold-standard antibody for the reliable detection and functional study of HLA-DR in human and closely related species, with key findings supporting its utility in specific and sensitive immune phenotyping and research on antigen presentation. The dosing regimens of clone L243, an antibody targeting human HLA-DR, can vary significantly across different mouse models. There is no universal dosing regimen for L243, as it is highly dependent on the specific experimental question, the degree of HLA-DR expression, and the type of mouse model being used (e.g., humanized vs. non-humanized models) . Key Considerations:
Unfortunately, there isn't a standard dosing regimen available for clone L243 across various studies, as each research context is unique. Therefore, titration and optimization of the antibody dose are recommended to achieve the desired experimental outcomes. References & Citations1. Moro M, Cecconi V, Martinoli C, et al. (2005) BMC Immunol. 6:24 2. Holling TM, et al. (2004) Hum Immunol. 65(4):282-90 3. Mitaksov V, (2006) J Biol Chem. 281(15):10618-25 4. Wieczorek M, et al. (2017) Front Immunol. 8:292 5. Artyomov MN, et al. (2010) Proc Natl Acad Sci USA. 107(39):16916-16921 6. Barnaba V, et al. (1994) Eur J Immunol. 24(1):71-5 7. Di Rosa F, et al. (1993) Hum Immunol. 38(4):251-60 8. Viallard JF, et al. (2001) Clin Exp Immunol. 125(3):485-491 9. Langford SE, Ananworanich J, Cooper DA. (2007) AIDS Res Ther. 2007;4:11 10. Gough SC, Simmonds MJ. (2007) Curr Genomics. 8(7):453-465 Technical ProtocolsCertificate of Analysis |
Related Products
Prod No. | Description |
---|---|
S211 | |
R1364 | |
I-118 | |
M1188 | |
C247 | |
F1175 | |
S571 |
Formats Available
Prod No. | Description |
---|---|
H131 | |
H132 | |
H133 | |
H1636 | |
H1637 | |
H1638 | |
H1640 | |
H500 | |
H134 | |
H261 | |
H241 | |
H461 |
